An orally bioavailable and ATP-competitive multi-AGC kinase inhibitor; inhibits Akt1, 2, and 3 (IC50s = 38, 402, and 50 nM, respectively); inhibits p70S6K, PKA, and ROCK-I and ROCK-II (IC50s = 3-8 nM); antiproliferative against cancer cell lines with genetic mutations in PI3K-Akt-mTOR or RAS-RAF pathways (GI50s = 1.54-3.77 μM); inhibits growth of MES-SA uterine sarcoma and BT474 breast cancer xenografts in mice (50 mg/kg, p.o.); inhibits ROCK-dependent phosphorylation of MLC2 over a 24-hour period in 4599 mouse melanoma cells (EC50 = 0.1 μM); reduces motility of 4699 melanoma cells in murine xenograft model